Oculis
phase a well tolerated by patients to me atone a | Oculis
Company
Deck Type
Deck date
April 2024
Slide
34 of 48
Related slides by other companies
Nuvectis Pharma
Investor Presentation
August 2023
phase underway fast track designation | Nuvectis Pharma
Fusion Pharmaceuticals
Investor Presentation
January 2024
program milestones patients | Fusion Pharmaceuticals
Equillium
Investor Presentation
December 2023
clinically validated in severe dermatological disease | Equillium
BioNTech
Results
November 2020
phase a safety profile | BioNTech
Other recent decks by Oculis
See all presentations (7 decks)
Results
August 2023
Investor Presentation
July 2023
Investor Conference
June 2023
Results
May 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io